Kazia Therapeutics Limited (NASDAQ:KZIA) Sees Significant Decrease in Short Interest

Kazia Therapeutics Limited (NASDAQ:KZIA) was the recipient of a large decrease in short interest during the month of January. As of January 15th, there was short interest totalling 5,600 shares, a decrease of 66.7% from the December 31st total of 16,800 shares. Based on an average daily volume of 133,400 shares, the short-interest ratio is currently 0.0 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Kazia Therapeutics stock. MAI Capital Management purchased a new position in shares of Kazia Therapeutics Limited (NASDAQ:KZIA) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,363,894 shares of the company’s stock, valued at approximately $586,000. MAI Capital Management owned 51.66% of Kazia Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 30.89% of the company’s stock.

Kazia Therapeutics Trading Down 3.2 %

NASDAQ:KZIA traded down $0.05 during trading hours on Tuesday, reaching $1.50. 14,702 shares of the company’s stock were exchanged, compared to its average volume of 87,167. Kazia Therapeutics has a 12 month low of $1.32 and a 12 month high of $15.80. The business’s 50-day simple moving average is $3.14 and its two-hundred day simple moving average is $3.96.

Kazia Therapeutics Company Profile

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.